Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol Myers Squibb Announces Record-breaking Dividend Increase

December 15, 2024
Bristol Myers Squibb Company (BMY) has made its mark once again by extending its 93-year dividend streak with a 16th consecutive annual increase. This announcement comes as no surprise, considering the company's impressive track record and commitment to delivering value to its shareholders.

The pharmaceutical giant, known for its groundbreaking treatments in areas such as oncology and immunology, has been a top performer in the industry. With a focus on developing innovative therapies that improve patients' lives, Bristol Myers Squibb has consistently delivered strong financial results and shareholder returns.

The company's commitment to shareholders is further highlighted by its socially responsible approach. Bristol Myers Squibb has been recognized as a top socially responsible dividend stock, offering a solid 4% yield. This allows investors to not only benefit from the company's financial success but also to support a company that prioritizes ethical business practices.

Investors looking to capitalize on Bristol Myers Squibb's continued success may consider seeking advice from professionals at Stocks Prognosis. With their expertise in analyzing market trends and predicting stock movements, Stocks Prognosis can provide valuable insights into the future performance of BMY stock.

As Bristol Myers Squibb continues to make waves in the pharmaceutical industry with its groundbreaking treatments and impressive financial performance, investors can rest assured that the company remains committed to delivering value and driving positive impact.
If you want to leave a comment, then you need Login or Register





Other data for BMY

Related data

BMYJune 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug  ~1 min.

Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....

BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success  ~2 min.

On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit  ~1 min.

On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit  ~1 min.

On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Target Forecast with 13.0% Profit - QuantWave Analysis  ~1 min.

On April 11, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price of $50.05....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 10.38% Profit: QuantWave Analysis  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY, a renowned pharmaceutical company, recently achieved its price target forecast set by QuantWave's automated forecasting platform....

ABBVDecember 18, 2024AbbVie Inc. ABBV to Acquire Nimble Therapeutics in a Game-Changing Move  ~1 min.

AbbVie Inc., a leading biopharmaceutical company, has announced its acquisition of Nimble Therapeutics, a pioneer in the field of immunology....

BIIBFebruary 27, 2025Biogen Inc. BIIB: A Promising Future for the Biotech Giant  ~2 min.

Biogen Inc., a leading biotech company, is making waves in the stock market with its groundbreaking research and development....

BMYJanuary 31, 2025Investors Heavily Search Bristol Myers Squibb Company BMY: Here is What You Need to Know  ~2 min.

According to recent reports, Bristol-Myers Squibb Company (NYSE: BMY) has caught the attention of investors, with institutional ownership reaching a staggering 77%....

AZNDecember 7, 2024Why AstraZeneca PLC AZN is Revolutionizing the Pharmaceutical Industry  ~2 min.

AstraZeneca PLC AZN, a leading multinational pharmaceutical company, is making groundbreaking strides in the industry....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....